Scientific Research News

AUCKLAND, New Zealand--(BUSINESS WIRE)--HPE (NYSE:HPE) today announced that Earth Sciences New Zealand (formally NIWA) of Aotearoa (New Zealand) selected HPE Cray XD2000, purpose-built for AI and simulation workloads, to accelerate the organization’s environmental science and precision of meteorological forecasting. The new system, named Cascade, replaces Earth Sciences New Zealand’s aging high performance computing (HPC) and delivers a threefold increase in computational power for researchers...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) injection for subcutaneous administration in adults across most solid tumor indications for KEYTRUDA® (pembrolizumab). Berahyaluronidase alfa is a variant of human hyaluronidase developed and manufactured by Alteogen Inc. KEYTRUDA QLEX must be administer...

ROCKVILLE, Md.--(BUSINESS WIRE)--BIOQUAL, Inc. www.bioqual.com BIOQ(Pinksheets):     2025     2024   Revenue $ 48,867,753   $ 58,590,949   (Loss) Income Before Income Tax $ (1,896,010 ) $ 476,447   Net (Loss) Income $ (1,048,154 ) $ 483,481   Basic Earnings per Share of Common Stock $ (1.17 ) $ .54   Diluted Earnings per Share of Common Stock $ (1.17 ) $ .54   Weighted Average           Number of Shares Outstanding           For Basic Earnings Per Share   894,416     894,416   Weighted Average...

YOKOHAMA, Japan--(BUSINESS WIRE)--The 2028 International Congress of the International Society of Blood Transfusion (ISBT 2028) will be held in Yokohama, Japan....

HYOGO, Japan--(BUSINESS WIRE)--JCR announced that is has achieved a key research milestone in one of its collaborative programs with Alexion, AstraZeneca Rare Disease....

SAN DIEGO--(BUSINESS WIRE)--Candid Therapeutics, Inc. (“Candid”), a clinical-stage biotechnology company redefining the treatment of autoimmune and inflammatory diseases through novel T-cell engagers (TCEs), today announced that it has been named to the prestigious 2025 Endpoints 11 list. The Endpoints 11 annually recognizes the most promising private biotech companies in the world driving innovation and shaping the future of the industry. “We are thrilled to receive this recognition after just...

BALLERUP, Denmark--(BUSINESS WIRE)--LEO Pharma: Late-Breaking Data at EADV 2025 Showing Week 16 Tralokinumab Response Predicts Long-Term Response in Moderate-to-Severe Atopic Dermatitis...

NANNING, China--(BUSINESS WIRE)--From September 17 to 19, the 4th China-ASEAN Meteorological Cooperation Forum kicked off in Nanning, Guangxi. Decision-makers, experts, and scholars from meteorological and hydrological departments of China and ASEAN countries such as Brunei, Cambodia, Laos, Vietnam, Thailand, Myanmar, and Indonesia, as well as from the World Meteorological Organization (WMO), universities, enterprises, and research institutions, gathered to discuss regional meteorological coope...

MINNEAPOLIS--(BUSINESS WIRE)--A study by the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) found that a donor search prognosis-based strategy helps physicians move patients with blood cancers and other blood diseases to hematopoietic cell transplant (HCT) faster, resulting in similar transplant success regardless of likelihood of finding a matched unrelated donor (MUD). Investigators from the consortium of U.S. transplant centers, CIBMTR® (Center for International Blood and Marr...

KYOTO & FUJISAWA, Japan--(BUSINESS WIRE)--xFOREST Therapeutics Co., Ltd. (“xFOREST”) and Axcelead Drug Discovery Partners, Inc. (“Axcelead DDP”) today announced the launch of a joint research collaboration aimed at developing RNA structure-targeted small molecule therapeutics for multiple diseases. xFOREST has developed a proprietary drug discovery platform, “FOREST Technologies,” which integrates a custom-designed RNA structure library and high-throughput screening technology. The platform spe...